Hemogenyx Pharmaceuticals PLC (HEMO) — Cash Flow-to-Debt Ratio
Hemogenyx Pharmaceuticals PLC (HEMO) has a Cash Flow-to-Debt Ratio of -0.53x as of December 2024, meaning its operating cash flow of GBX-1.78 Million could theoretically repay -1% of its total liabilities (GBX3.36 Million) in one year. See Hemogenyx Pharmaceuticals PLC (HEMO) financial flexibility to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Hemogenyx Pharmaceuticals PLC Cash Flow-to-Debt Ratio (2015–2024)
Historical debt coverage capacity for Hemogenyx Pharmaceuticals PLC across 10 annual periods. For the full cash flow conversion analysis, see Hemogenyx Pharmaceuticals PLC cash conversion from operations.
Annual Cash Flow-to-Debt Ratio for Hemogenyx Pharmaceuticals PLC (2015–2024)
Year-by-year debt coverage analysis for Hemogenyx Pharmaceuticals PLC. Check HEMO cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (GBX) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.23x | GBX-4.12 Million | GBX3.36 Million | ▲ +33.2% |
| 2023 | -1.84x | GBX-6.11 Million | GBX3.32 Million | ▼ -142.8% |
| 2022 | -0.76x | GBX-2.91 Million | GBX3.85 Million | ▲ +89.8% |
| 2021 | -7.45x | GBX-2.63 Million | GBX352.84K | ▼ -640.7% |
| 2020 | -1.01x | GBX-1.80 Million | GBX1.79 Million | ▼ -17.2% |
| 2019 | -0.86x | GBX-1.20 Million | GBX1.40 Million | ▲ +15.0% |
| 2018 | -1.01x | GBX-1.35 Million | GBX1.34 Million | ▲ +41.3% |
| 2017 | -1.72x | GBX-452.98K | GBX263.69K | ▲ +11.3% |
| 2016 | -1.94x | GBX-278.15K | GBX143.69K | ▼ -599506.7% |
| 2015 | 0.00x | GBX79.71 | GBX246.83K | — |